EGI
About EGI

Background

egi egi egi
3 million Americans and 65 million people worldwide have epilepsy ~30-40% of Americans with epilepsy (~1 million) have uncontrolled seizures despite the many currently-available treatments ~70% of Americans with epilepsy (~2.1 million) don’t know the cause of their epilepsy

Most people don’t know the cause of their epilepsy,
but genetics is changing that.

Causes of Epilepsy

How is genetic research
leading to personalized medicine?

CLICK HERE to read more

DNA is the genetic material in each of us that makes us who we are. Your DNA is made up of genes (about 20,000 of them). Each of your genes carries a unique DNA code, and that code is what determines your traits (such as eye color, size, and even behavior).

DNA changes happen all the time in living things, and this alters the genetic code. But sometimes a change in the genetic code can have negative consequences, like developing a medical condition such as epilepsy.

Dozens of altered genes have already been identified in people with epilepsy, but most don’t know the cause of their seizures or if they are genetic. That’s where EGI comes in. In some cases, we can use genetics to identify the different causes of epilepsy.

Why do we want to know the cause? Because knowing the cause of your epilepsy can already shed some light on which drugs might or might not be right for you (in some cases). But ultimately, we believe this type of information will help doctors figure out which treatment works best for the different kinds of epilepsy and that knowing causes will ultimately help us find cures.

Using genetics to diagnose and treat is our goal and we hope it will lead us to a future of personalized medicine for people with epilepsy.

Currently, people with epilepsy may have their DNA sequenced through their doctor via a certified lab. This testing looks for changes in their DNA code that may be causing their epilepsy. The kind of testing we are talking about is called 'exome sequencing.' This test looks at the code in all the genes in your body and reports back on any relevant findings.

But, during this testing, the data are typically analyzed only once by the lab and only genetic changes proven to cause epilepsy at the time of reporting are shared. This means that any newly identified genetic causes of epilepsy will not be reported.

To address this, CURE has created EGI. EGI is a database where patients, with the help of their doctors, can send their exome data and have them analyzed and reanalyzed in an effort to find the cause of their epilepsy. Any important findings will be reported back to the patient’s doctor. But EGI doesn’t stop there. EGI will also allow patients to participate in research that will help scientists find new causes of epilepsy. This is done by allowing researchers to study all the DNA codes we collect in EGI (all confidentially of course).

With the ability to study a lot of people’s DNA, researchers also want to determine things like which drugs are best (and worst) for the different kinds of epilepsy, and why some people with epilepsy have coexisting conditions like depression and learning and memory problems. This is a major goal of EGI – to advance research in epilepsy.

In the end, everybody wins.
EGI brings together patients, medical professionals and scientists – with patients leading the way. The goal? To create a mutually beneficial partnership that will improve the diagnosis and treatment of people with epilepsy in a way that leads us to cures.


FAQ

EGI was created for patients, doctors and researchers; we have assembled frequently asked questions (FAQs) that cater to each specific audience. Click below to find the FAQs most relevant to you:


data collectedAbout the Data Being Collected in EGI

Upon consent from the patient, EGI will collect exome sequence data directly from the certified diagnostic lab that has done the testing.  In addition, the patient’s doctor will fill out the EGI Clinical Data form.  The de-identified* personal health information to be collected by EGI includes:

  • Demographics (date of birth, age, gender, race and ethnicity)
  • Family history of epilepsy and other relevant medical conditions
  • Birth and neonatal history
  • Epilepsy history (risk factors, age of first seizure, seizure type(s), EEG results and neuroimaging results)
  • Development/cognition information (development delays, IQ)
  • Other medical conditions that are present in the patient
  • Abnormal genetic or metabolic testing
  • Epilepsy classification, syndrome, etiology, response to treatments and outcome
  • Is the patient in any other databases/studies? (e.g. Epi4K, EPGP, PERC, REN, Seizure Tracker, etc.)
  • Extreme positive or negative response to a therapy
  • Info on who is completing the form/date

*All personal health information will be confidential (de-identified, all the identifying information will be removed). Each patient will be assigned a research number and only that number will be associated with the patient’s data. All data will be collected in a secure, fully compliant manner and in full accordance with the laws.


EGI Organizational Structure

Origins of EGI: EGI was born out of discussions between CURE, the National Institute of Neurological Disorders and Stroke (NINDS), and the EGI Investigators, Sam Berkovic, David Goldstein, Erin Heinzen Cox, and Dan Lowenstein. The goal was to find a way to bridge the gap between the need for patients to have their exome data repeatedly analyzed and the important contribution these data could make to further epilepsy research.

How is EGI Governed? Below is a diagram that depicts how EGI is structured and a description of what each committee does:

Org Chart

Steering Committee
This committee will provide big picture guidance on all aspects of the project including, but not limited to, future growth strategies, organizational structure, EGI goals and EGI policies and procedures. The Steering Committee is made up of members of CURE and NINDS.

See Members

H. Steve White, PhD – CURE
Tracy Dixon-Salazar, PhD – CURE
Julie Milder, PhD – CURE
Vicky Holets-Whittemore, PhD – NINDS
Brandy Fureman, PhD – NINDS

Key Advisors:
Sam Berkovic, MD – University of Melbourne
David Goldstein, PhD – Columbia University
Erin Heinzen Cox, PhD – Columbia University
Dan Lowenstein, MD – University of California, San Francisco


Oversight Committee
The Steering Committee is working to establish an Oversight Committee made up of 5-10 members who are not a part of the EGI project but have relevant expertise. Expertise may include, but is not limited to, statistics, genetics, neurological disorders, bioinformatics, legal aspects of data repositories and industry. Advisors may be consulted on any number of issues relevant to EGI including, but not limited to, overall Structurestrategies for the growth and longevity of EGI, EGI structure and function, prioritization of project goals, implementation of policies and procedures, conformance with regulatory provisions and data sharing.

Members:TBD


EGI Access Committee
CURE is working to establish an independent EGI Access Committee (EAC), which it will oversee. In 2015, the EAC will evaluate requests seeking access to the data and will evaluate proposals for publications making use of EGI data. The EAC will be responsible for the transparency and integrity of the data in the repository and the avoidance of conflicts of interest. The EAC will carefully track all EGI-related research and publications in order to prevent duplication of efforts as it relates to research using data in the EGI repository. The EAC will be made up of members of CURE’s Research Team and other outside advisors.

See Members

Tracy Dixon-Salazar, PhD – CURE
Randall Stewart, PhD – NINDS


Administrative Committee
Members of this committee are the stewards of EGI and act as a checkpoint to ensure that EGI activities conform to any agreed-upon universal protocols, follow regulatory provisions and maintain data confidentiality. The Administrative Groups, listed below and overseen by the EGI Investigators, provide this committee with the needed information to act as appropriate stewards. The Administrative Committee includes members of the CURE Research Team and the EGI Investigators.

See Members

Sam Berkovic, MD – University of Melbourne
David Goldstein, PhD – Columbia University
Erin Heinzen Cox, PhD – Columbia University
Dan Lowenstein, MD – University of California, San Francisco
Tracy Dixon-Salazar, PhD – CURE


Data Group
This group reports to the Administrative Committee and oversees all matters of data collection, entry, storage, quality control and processing as it relates to EGI. The Data group also oversees the initial and biannual analysis of the EGI data set for potential disease causing variants.

See Members

Erin Heinzen Cox, PhD – Columbia University
Louise Bier – Columbia University
Tracy Dixon-Salazar, PhD – CURE


Enrollment Group
This group reports to the Administrative Committee and oversees all matters of enrolling patients in the study, partnering with medical centers and facilitating collection of the genetic and phenotypic data.

See Members

Tracy Dixon-Salazar, PhD – CURE
Brandy Fureman, PhD – NINDS
Erin Heinzen Cox, PhD – Columbia University
Louise Bier, MS, CGC – Columbia University
Mohamad Makati, MD – Duke University
William Gallentine, DO – Duke University
Dennis Dlugos, MD – Children’s Hospital of Philadelphia
Ingo Helbig, MD – Children’s Hospital of Philadelphia
Eric Marsh, MD – Children’s Hospital of Philadelphia
Holly Dubbs, CGC – Children’s Hospital of Philadelphia
Joe Sullivan, MD – University of California San Francisco
Nilika Singhal, MD – University of California San Francisco
Maria Roberta Cilio, MD – University of California San Francisco
Susannah Cornes, MD – University of California San Francisco
Ingrid Scheffer, MD – University of Melbourne
Bronwyn Grinton – University of Melbourne
Annapurna Poduri, MD. MPH – Boston Children’s Hospital
Beth Sheidley, MS, CGC – Boston Children’s Hospital
Lacey Smith, MS, CGC – Boston Children’s Hospital
Orrin Devinsky, MD – New York University Langone School of Medicine
Nako Ishii – New York University Langone School of Medicine
John Millichap, MD – Ann and Robert H. Lurie Children’s Hospital of Chicago
Diana Miazga – Ann and Robert H. Lurie Children’s Hospital of Chicago


Patient Reporting Group
This group reports to the Administrative Committee and oversees all matters of reporting data to patients including de-identification of all data, determination of what is to be reported (pathogenic variants) and reporting findings back to the patient’s doctor.

Members:TBD


 

GLOSSARY OF TERMS
Glossary
Need help with a DNA term? Find out what it all means with our handy Glossary of Terms.



 

CURE
CURE's mission is to cure epilepsy, transforming and saving millions of lives. We identify and fund cutting-edge research,
challenging scientists worldwide to collaborate and innovate in pursuit of this goal. Our commitment is unrelenting.
Instagram
YouTube